View Clinical Trial (Medical Research Study)

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers - NCT00587496-70112(Clinical Trial 197273)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New Orleans
State:  
LA
Zip Code: 70112
Conditions: Herpes Simplex
Purpose: The purpose of this study is to determine whether oral Valtrex alone or in combination with aspirin will reduce the shedding of herpes simplex virus DNA in the tears and saliva from volunteers with no evidence of ocular herpes infection. The secretion of virus into the tears and saliva might make people more susceptible to virus infection in the future if their immune system becomes deficient. The study will also try to determine if there is a correlation between shedding of viral DNA and herpes virus antibodies in serum and to determine if subjects are carriers of a special form of a gene in their blood cells, the presence of which may suggest the possibility of an increased susceptability to herpes and to Alzheimer's disease and heart disease.
Study summary: Published studies have shown that treatment with oral acyclovir reduced clinical recurrences of ocular herpetic keratitis by about 40-50 %8, and treatment with valacyclovir, a more soluble prodrug of acyclovir, reduced the risk of transmission of genital herpes9, 10, 11. For this study, we will use the dose of valacyclovir that was shown effective in reducing the risk of transmission of HSV-2.9 The dose of 325 mg aspirin three times a day was chosen based on our experience with mice and other laboratory animals12. If it is effective and well tolerated at this dose, in future studies we will attempt to use lower doses and determine if they too may be effective.
Criteria: Inclusion Criteria: - either sex - any race - over age of 21 years Exclusion Criteria: - have active ocular herpetic lesion - had ocular herpetic lesion in past 30 days - taking systemic or oral antiviral drugs - have taken antiviral drugs in the past 30 days - taking aspirin or NSAIDs - have dry eyes - have hypersensitivity to acyclovir or valacyclovir - have hypersensitivity of contraindication to use of aspirin - have bleeding disorder - have GI ulcer - have kidney impairment - are pregnant or nursing - have participated in a clinical trial in the past 30 days
Study is available at: LSU Eye Center
New Orleans, LA 70112
United States

Primary Contact:
Emily D Varnell, BS
Email: evarne@lsuhsc.edu
Phone: 504 568-2254
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.